Header Logo

Connection

JOSEPH JANKOVIC to Severity of Illness Index

Back to Details
This is a "connection" page, showing publications JOSEPH JANKOVIC has written about Severity of Illness Index.
JOSEPH JANKOVIC
Connection Strength
2.329
Severity of Illness Index
  1. Axial tics in Tourette syndrome and chronic tic disorders. J Neurol. 2024 Nov; 271(11):7232-7238.
    View in: PubMed
    Score: 0.128
  2. Functional Neurological Disorders Among Patients With Tremor. J Neuropsychiatry Clin Neurosci. 2025; 37(1):61-66.
    View in: PubMed
    Score: 0.127
  3. Cervical dystonia and substance abuse. J Neurol. 2018 Apr; 265(4):970-975.
    View in: PubMed
    Score: 0.082
  4. Clinimetric testing of the comprehensive cervical dystonia rating scale. Mov Disord. 2016 Apr; 31(4):563-9.
    View in: PubMed
    Score: 0.071
  5. Psychogenic Ophthalmologic Movement Disorders. J Neuropsychiatry Clin Neurosci. 2016; 28(3):195-8.
    View in: PubMed
    Score: 0.070
  6. Dopamine transporter imaging in essential tremor with and without parkinsonian features. J Neural Transm (Vienna). 2015 Nov; 122(11):1515-21.
    View in: PubMed
    Score: 0.068
  7. Deep brain stimulation of the subthalamic nucleus for peripherally induced parkinsonism. Neuromodulation. 2014 Jan; 17(1):104-6.
    View in: PubMed
    Score: 0.058
  8. Reliability of a new scale for essential tremor. Mov Disord. 2012 Oct; 27(12):1567-9.
    View in: PubMed
    Score: 0.056
  9. Long-term safety and tolerability of rotigotine transdermal system in patients with early-stage idiopathic Parkinson's disease: a prospective, open-label extension study. Parkinsonism Relat Disord. 2012 Jun; 18(5):488-93.
    View in: PubMed
    Score: 0.053
  10. Reflexive and volitional saccades: biomarkers of Huntington disease severity and progression. J Neurol Sci. 2012 Feb 15; 313(1-2):35-41.
    View in: PubMed
    Score: 0.052
  11. Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin) in the treatment of blepharospasm-a randomized trial. Mov Disord. 2011 Jul; 26(8):1521-8.
    View in: PubMed
    Score: 0.051
  12. A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol. 2011 May; 10(5):415-23.
    View in: PubMed
    Score: 0.050
  13. Clinical efficacy and tolerability of Xeomin in the treatment of blepharospasm. Eur J Neurol. 2009 Dec; 16 Suppl 2:14-8.
    View in: PubMed
    Score: 0.046
  14. A randomised, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome. J Neurol Neurosurg Psychiatry. 2010 Jan; 81(1):70-3.
    View in: PubMed
    Score: 0.045
  15. Efficacy and tolerability of pregabalin in essential tremor: a randomized, double-blind, placebo-controlled, crossover trial. J Neurol Sci. 2009 Oct 15; 285(1-2):195-7.
    View in: PubMed
    Score: 0.045
  16. Atomoxetine for freezing of gait in Parkinson disease. J Neurol Sci. 2009 Sep 15; 284(1-2):177-8.
    View in: PubMed
    Score: 0.044
  17. Relationship between various clinical outcome assessments in patients with blepharospasm. Mov Disord. 2009 Feb 15; 24(3):407-13.
    View in: PubMed
    Score: 0.043
  18. Applause sign in Parkinsonian disorders and Huntington's disease. Mov Disord. 2008 Dec 15; 23(16):2307-11.
    View in: PubMed
    Score: 0.043
  19. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008 Nov 15; 23(15):2129-70.
    View in: PubMed
    Score: 0.043
  20. A study of chorea after tetrabenazine withdrawal in patients with Huntington disease. Clin Neuropharmacol. 2008 May-Jun; 31(3):127-33.
    View in: PubMed
    Score: 0.041
  21. Overnight switch from oral dopaminergic agonists to transdermal rotigotine patch in subjects with Parkinson disease. Clin Neuropharmacol. 2007 Sep-Oct; 30(5):256-65.
    View in: PubMed
    Score: 0.039
  22. Distinguishing psychogenic and essential tremor. J Neurol Sci. 2007 Dec 15; 263(1-2):94-9.
    View in: PubMed
    Score: 0.039
  23. Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease. Arch Neurol. 2007 May; 64(5):676-82.
    View in: PubMed
    Score: 0.038
  24. Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov Disord. 2007 Jan 15; 22(2):193-7.
    View in: PubMed
    Score: 0.038
  25. Short-term effects of tetrabenazine on chorea associated with Huntington's disease. Mov Disord. 2007 Jan; 22(1):10-3.
    View in: PubMed
    Score: 0.037
  26. Joint and skeletal deformities in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Mov Disord. 2006 Nov; 21(11):1856-63.
    View in: PubMed
    Score: 0.037
  27. Psychogenic tremor: long-term outcome. CNS Spectr. 2006 Jul; 11(7):501-8.
    View in: PubMed
    Score: 0.036
  28. Globus pallidus deep brain stimulation in dystonia. Mov Disord. 2006 May; 21(5):692-5.
    View in: PubMed
    Score: 0.036
  29. Modafinil for daytime somnolence in Parkinson's disease: double blind, placebo controlled parallel trial. J Neurol Neurosurg Psychiatry. 2005 Dec; 76(12):1636-9.
    View in: PubMed
    Score: 0.035
  30. Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations. Mov Disord. 2005; 20 Suppl 11:S11-6.
    View in: PubMed
    Score: 0.033
  31. Factor analysis and clustering of motor and psychiatric dimensions in idiopathic blepharospasm. Parkinsonism Relat Disord. 2025 Feb; 131:107241.
    View in: PubMed
    Score: 0.033
  32. An open-label pilot study of levetiracetam for essential tremor. Clin Neuropharmacol. 2004 Nov-Dec; 27(6):274-7.
    View in: PubMed
    Score: 0.032
  33. Atypical parkinsonism and motor neuron syndrome in a Biosphere 2 participant: a possible complication of chronic hypoxia and carbon monoxide toxicity? Mov Disord. 2004 Apr; 19(4):465-9.
    View in: PubMed
    Score: 0.031
  34. Premonitory sensory phenomenon in Tourette's syndrome. Mov Disord. 2003 Dec; 18(12):1530-3.
    View in: PubMed
    Score: 0.030
  35. Hearing impairment in essential tremor. Neurology. 2003 Oct 28; 61(8):1093-7.
    View in: PubMed
    Score: 0.030
  36. Head injury and posttraumatic movement disorders. Neurosurgery. 2002 May; 50(5):927-39; discussion 939-40.
    View in: PubMed
    Score: 0.027
  37. A double-blind, placebo-controlled and longitudinal study of riluzole in early Parkinson's disease. Parkinsonism Relat Disord. 2002 Mar; 8(4):271-6.
    View in: PubMed
    Score: 0.027
  38. Dystonia in spinocerebellar ataxia type 6. Mov Disord. 2002 Jan; 17(1):150-3.
    View in: PubMed
    Score: 0.027
  39. Quantitative mobility measures complement the MDS-UPDRS for characterization of Parkinson's disease heterogeneity. Parkinsonism Relat Disord. 2021 03; 84:105-111.
    View in: PubMed
    Score: 0.025
  40. Re-emergence of childhood stuttering in Parkinson's disease: a hypothesis. Mov Disord. 2001 Jan; 16(1):114-8.
    View in: PubMed
    Score: 0.025
  41. Computerized posturography analysis of progressive supranuclear palsy: a case-control comparison with Parkinson's disease and healthy controls. Arch Neurol. 2000 Oct; 57(10):1464-9.
    View in: PubMed
    Score: 0.024
  42. Understanding the relationship between freezing of gait and other progressive supranuclear palsy features. Parkinsonism Relat Disord. 2020 09; 78:56-60.
    View in: PubMed
    Score: 0.024
  43. Tardive and idiopathic oromandibular dystonia: a clinical comparison. J Neurol Neurosurg Psychiatry. 2000 Feb; 68(2):186-90.
    View in: PubMed
    Score: 0.023
  44. Minimal clinically important change in patients with cervical dystonia: Results from the CD PROBE study. J Neurol Sci. 2019 Oct 15; 405:116413.
    View in: PubMed
    Score: 0.022
  45. Interrogating the Genetic Determinants of Tourette's Syndrome and Other Tic Disorders Through Genome-Wide Association Studies. Am J Psychiatry. 2019 03 01; 176(3):217-227.
    View in: PubMed
    Score: 0.022
  46. Ecopipam, a D1 receptor antagonist, for treatment of tourette syndrome in children: A randomized, placebo-controlled crossover study. Mov Disord. 2018 08; 33(8):1272-1280.
    View in: PubMed
    Score: 0.021
  47. Benefits and risks of unilateral and bilateral ventral intermediate nucleus deep brain stimulation for axial essential tremor symptoms. Parkinsonism Relat Disord. 2019 03; 60:126-132.
    View in: PubMed
    Score: 0.021
  48. Consensus for the measurement of the camptocormia angle in the standing patient. Parkinsonism Relat Disord. 2018 07; 52:1-5.
    View in: PubMed
    Score: 0.021
  49. Safety of Converting From Tetrabenazine to Deutetrabenazine for the Treatment of Chorea. JAMA Neurol. 2017 08 01; 74(8):977-982.
    View in: PubMed
    Score: 0.020
  50. Psychiatric associations of adult-onset focal dystonia phenotypes. J Neurol Neurosurg Psychiatry. 2017 07; 88(7):595-602.
    View in: PubMed
    Score: 0.019
  51. Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial. JAMA Neurol. 2017 Feb 01; 74(2):216-224.
    View in: PubMed
    Score: 0.019
  52. Cross-disorder genome-wide analyses suggest a complex genetic relationship between Tourette's syndrome and OCD. Am J Psychiatry. 2015 Jan; 172(1):82-93.
    View in: PubMed
    Score: 0.016
  53. IncobotulinumtoxinA (Xeomin?) injected for blepharospasm or cervical dystonia according to patient needs is well tolerated. J Neurol Sci. 2014 Nov 15; 346(1-2):116-20.
    View in: PubMed
    Score: 0.016
  54. Use of botulinum toxin in the treatment of hand dystonia. J Hand Surg Am. 1993 Sep; 18(5):883-7.
    View in: PubMed
    Score: 0.015
  55. How to identify tremor dominant and postural instability/gait difficulty groups with the movement disorder society unified Parkinson's disease rating scale: comparison with the unified Parkinson's disease rating scale. Mov Disord. 2013 May; 28(5):668-70.
    View in: PubMed
    Score: 0.014
  56. Subthalamic deep brain stimulation with a constant-current device in Parkinson's disease: an open-label randomised controlled trial. Lancet Neurol. 2012 Feb; 11(2):140-9.
    View in: PubMed
    Score: 0.013
  57. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol. 2011 Mar; 69(3):570-80.
    View in: PubMed
    Score: 0.013
  58. Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol. 2010 Dec; 9(12):1164-1172.
    View in: PubMed
    Score: 0.012
  59. Variable expression of Parkinson's disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group. Neurology. 1990 Oct; 40(10):1529-34.
    View in: PubMed
    Score: 0.012
  60. Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia. Parkinsonism Relat Disord. 2010 Jun; 16(5):316-23.
    View in: PubMed
    Score: 0.012
  61. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain. 2010 Mar; 133(Pt 3):713-26.
    View in: PubMed
    Score: 0.012
  62. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med. 2009 Sep 24; 361(13):1268-78.
    View in: PubMed
    Score: 0.011
  63. Clinical, biochemical, and neuropathologic findings following transplantation of adrenal medulla to the caudate nucleus for treatment of Parkinson's disease. Neurology. 1989 Sep; 39(9):1227-34.
    View in: PubMed
    Score: 0.011
  64. The course of depressive symptoms in early Parkinson's disease. Mov Disord. 2009 Jul 15; 24(9):1306-11.
    View in: PubMed
    Score: 0.011
  65. Depressed mood and memory impairment before and after unilateral posteroventral pallidotomy in Parkinson's disease. J Neuropsychiatry Clin Neurosci. 2008; 20(3):357-63.
    View in: PubMed
    Score: 0.010
  66. Short and long-term motor and cognitive outcome of staged bilateral pallidotomy: a retrospective analysis. Acta Neurochir (Wien). 2007; 149(9):857-66; discussion 866.
    View in: PubMed
    Score: 0.010
  67. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord. 2007 Jan; 22(1):41-7.
    View in: PubMed
    Score: 0.009
  68. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol. 2004 Jul; 61(7):1044-53.
    View in: PubMed
    Score: 0.008
  69. Thalamic deep brain stimulation: effects on the nontarget limbs. Mov Disord. 2001 Nov; 16(6):1137-42.
    View in: PubMed
    Score: 0.007
  70. Weight gain following unilateral pallidotomy in Parkinson's disease. Acta Neurol Scand. 2000 Feb; 101(2):79-84.
    View in: PubMed
    Score: 0.006
  71. Symptomatic and functional outcome of surgical treatment of cervical dystonia. J Neurol Neurosurg Psychiatry. 1997 Nov; 63(5):642-8.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.